Table 3.

Spearman correlations between insulin sensitivity indexes and CMR parameters at baseline and their differences between baseline and seven months, in the empagliflozin and in the placebo groups

Empagliflozin

LVMi

LVESVi

LVEF

LVEDVi

LVSVi

ECV

∆LVMi

∆LVESVi

∆LVEF

∆LVEDVi

∆LVSVi

∆ECV

Stumvoll MCR120

− 0.86*

0.27

− 0.17

0.32

− 0.36

− 0.02

HOMA2S

− 0.65*

0.51

− 0.32

0.63*

− 0.05

− 0.08

QUICKI

− 0.56*

0.43

− 0.23

0.53

− 0.02

− 0.21

∆Stumvoll MCR120

− 0.35

0.28

− 0.01

0.49

0.32

0.18

∆HOMA2S

− 0.13

0.80*

− 0.40

0.79*

0.12

0.04

∆QUICKI

− 0.27

0.81*

− 0.41

0.82*

0.14

− 0.06

Placebo

LVMi

LVESVi

LVEF

LVEDVi

LVSVi

ECV

∆LVMi

∆LVESVi

∆LVEF

∆LVEDVi

∆LVSVi

∆ECV

Stumvoll MCR120

− 0.78*

0.35

− 0.36

0.26

− 0.22

0.18

HOMA2S

− 0.48*

0.60*

− 0.53*

0.50*

0.06

0.31

QUICKI

0.41

0.56*

− 0.46*

0.48*

0.11

0.21

∆Stumvoll MCR120

− 0.59*

− 0.09

0.13

0.003

− 0.02

− 0.12

∆HOMA2S

− 0.08

− 0.24

0.33

0.12

0.21

0.02

∆QUICKI

0.03

− 0.36

0.36

− 0.02

0.15

0.14

* p ≤ 0.05

HOMA, Homeostasis model assessment; ISI, insulin sensitivity index; Stumvoll MCR₁₂₀, metabolic clearance rate QUICKI, quantitative insulin sensitivity check index